Precigen, Inc.
PGENPrecigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How PGEN's past catalysts played out
PRGN-2009 plus Pembrolizumab
Cervical Cancer
PRGN-2012 - Phase I; Dose Level 1
Recurrent Respiratory Papillomatosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRGN-2009 plus Pembrolizumab | Phase 2 | Cervical Cancer | - | - |
PRGN-2012 - Phase I; Dose Level 1 | Phase 2 | Recurrent Respiratory Papillomatosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Precigen, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Precigen, Inc.'s (PGEN) pipeline across Phase 2. Its lead program is PRGN-2009 plus Pembrolizumab (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Precigen, Inc.'s next FDA catalyst?→
Precigen, Inc.'s (PGEN) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PGEN biotech catalysts?→
Add PGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Precigen, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.